Biobank for prostate tissue samples and genetic data
Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease
This study is collecting prostate tissue samples and DNA from men with inherited gene mutations to see how these genetic factors affect prostate cancer and treatment responses compared to men without these mutations.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT06659614 on ClinicalTrials.gov |
What this trial studies
This study aims to create a biorepository of prostate tissue samples and matched germline DNA from men with inherited gene mutations linked to prostate cancer, as well as age-matched controls. It focuses on understanding the development of prostate cancer and treatment responses in carriers of specific genetic mutations compared to non-carriers. By collecting and analyzing these samples, researchers hope to gain insights into the genetic factors influencing prostate cancer outcomes.
Who should consider this trial
Good fit: Ideal candidates include men with confirmed pathogenic variants in prostate cancer risk genes and those undergoing prostate biopsies or prostatectomies.
Not a fit: Patients without a genetic predisposition to prostate cancer or those not undergoing relevant procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of prostate cancer genetics and improve personalized treatment strategies for affected patients.
How similar studies have performed: Other studies have shown success in utilizing biobanks for genetic research in cancer, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Carriers (Group 1): 1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene. 2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer Controls (Group 2): 1\. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer Exclusion Criteria: * N/A
Where this trial is running
Philadelphia, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Kara N Maxwell, MD, PhD — University of Pennsylvania
- Study coordinator: Kara N Maxwell, MD, PhD
- Phone: 215-898-9698
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.